Bruce Leuchter, CEO, Neurvati, explains why aligning drug development with patient-reported outcomes is key to demonstrating value and achieving payer alignment in the rare disease space.

Expert panelists emphasize the importance of trusted data sources, strong payer partnerships, economic incentives, and ...

A qualitative study explores how MA plan leaders, kidney care managers, and dialysis providers perceive the benefits, risks, ...

In the first part of his Pharma Commerce video interview, Marschall Runge, MD, PhD, dean of the University of Michigan ...

Bruce Leuchter, CEO, Neurvati, discusses why patient engagement is essential to understanding rare diseases and driving the ...

In the final part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, predicts ...

The company joins a wave of global pharma companies reshoring operations to strengthen the US supply chain and meet patient ...

As drug development increasingly targets multiple indications, pharma companies must make strategic branding ...

Bruce Leuchter, CEO, Neurvati, discusses the vital role of public participation in healthcare policy, highlighting how ...

State Medicaid leaders create a plan to ensure safety, affordability, and equitable access for children and families living with rare diseases.

The Impact of FDA’s Ban on Compounded GLP-1s A Pharmaceutical Executive article explores how the FDA’s ban on compounded semaglutides—following stabilized supply from Novo Nordisk and Eli Lilly—has ...